PEN vs. GEHC, PHG, ZBH, SOLV, SNN, GKOS, BLCO, STVN, INSP, and NARI
Should you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew (SNN), Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), Inspire Medical Systems (INSP), and Inari Medical (NARI). These companies are all part of the "medical equipment" industry.
Penumbra vs.
GE HealthCare Technologies (NASDAQ:GEHC) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
GE HealthCare Technologies has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.
GE HealthCare Technologies has a net margin of 10.13% compared to Penumbra's net margin of 1.17%. GE HealthCare Technologies' return on equity of 25.74% beat Penumbra's return on equity.
In the previous week, GE HealthCare Technologies had 11 more articles in the media than Penumbra. MarketBeat recorded 20 mentions for GE HealthCare Technologies and 9 mentions for Penumbra. GE HealthCare Technologies' average media sentiment score of 1.38 beat Penumbra's score of 0.37 indicating that GE HealthCare Technologies is being referred to more favorably in the media.
Penumbra received 805 more outperform votes than GE HealthCare Technologies when rated by MarketBeat users. Likewise, 80.25% of users gave Penumbra an outperform vote while only 60.00% of users gave GE HealthCare Technologies an outperform vote.
82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.3% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 5.0% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
GE HealthCare Technologies currently has a consensus target price of $97.67, suggesting a potential upside of 15.23%. Penumbra has a consensus target price of $292.64, suggesting a potential upside of 2.36%. Given GE HealthCare Technologies' higher probable upside, analysts plainly believe GE HealthCare Technologies is more favorable than Penumbra.
GE HealthCare Technologies has higher revenue and earnings than Penumbra. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
Summary
GE HealthCare Technologies and Penumbra tied by winning 9 of the 18 factors compared between the two stocks.
Get Penumbra News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Penumbra Competitors List
Related Companies and Tools
This page (NYSE:PEN) was last updated on 3/6/2025 by MarketBeat.com Staff
